Literature DB >> 9365536

Molecular mechanisms of melanoma metastasis.

M Bar-Eli1.   

Abstract

The molecular changes associated with the transition of melanoma cells from radial growth phase to vertical growth phase (metastatic phenotype) are not very well defined. Expression of the tyrosine-kinase receptor c-KIT progressively decreases during local tumor growth and invasion of human melanomas. To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into c-KIT-negative, highly metastatic human melanoma cells and subsequently analyzed their tumorigenic and metastatic potential in nude mice. Enforced c-KIT expression significantly inhibited tumor growth and metastasis. Exposure of c-KIT-positive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for c-KIT, triggered apoptosis of these cells but not of normal melanocytes. These results suggest that the loss of c-KIT receptor may allow malignant melanoma cells to escape SCF/c-KIT-mediated apoptosis, thus contributing to tumor growth and eventually metastasis. The expression of c-KIT and other genes associated with malignant melanoma (such as MCAM/MUC18) is highly regulated by the transcription factor AP-2. The AP-2 protein is not expressed in malignant melanoma cells. Therefore, loss of AP-2 expression might be a crucial event in the progression of human melanoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365536     DOI: 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

1.  Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.

Authors:  O Nyormoi; Z Wang; D Doan; M Ruiz; D McConkey; M Bar-Eli
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

3.  Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family.

Authors:  D Jean; M Bar-Eli
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

4.  Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation.

Authors:  K M Ropponen; J K Kellokoski; R T Pirinen; K I Moisio; M J Eskelinen; E M Alhava; V M Kosma
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

Review 5.  Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Authors:  Russell R Braeuer; Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Menashe Bar-Eli
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

Review 6.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

7.  Primary cutaneous melanoma: an 18-year study.

Authors:  Moris Anger; Henri Friedhofer; Marina Fussae Fukutaki; Marcus Castro Ferreira; Gilles Landman
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

8.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 9.  The biology and management of uveal melanoma.

Authors:  Takami Sato; Fei Han; Akira Yamamoto
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

10.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

Authors:  Gabriel J Villares; Maya Zigler; Hua Wang; Vladislava O Melnikova; Hong Wu; Ran Friedman; Michael C Leslie; Pablo E Vivas-Mejia; Gabriel Lopez-Berestein; Anil K Sood; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.